Advanced BioMatrix (ABM) has acquired the HyStem® line of products from Lineage Cell Therapeutics (LCT)

This acquisition includes the transfer of technology, intellectual property, know-how and assets for the manufacturing and sale of HyStem^® products for research and development purposes. ABM and LTC are working closely together to ensure an efficient and seamless handover of the manufacturing, testing and distribution of products to users of the HyStem^® products.

CellSystems offers the portfolio of HyStem^® products for research in Europe now.

HyStem^®  GS311F

HyStem^® – C  GS313F

HyStem^® – HP GS315F